November 2022

EVAXION

Saving lives with AI-powered immunotherapies



Forward-looking statement

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expec[a]t," "hope," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including risks and uncertainties relating to: the implementation of our business model and our plans to develop and commercialize our lead product candidates and other product candidates, including the potential benefits thereof; our ongoing and future clinical trials for our lead product candidates, whether conducted by us or by any of our collaborators and partners, including the timing of initiation of these trials and of the anticipated results; our pre-clinical studies and future clinical trials for our other product candidates and our research and development programs, whether conducted by us or by any of our collaborators and partners, including the timing of initiation of these trials and of the anticipated results; the timing of and our ability to obtain and maintain regulatory and marketing approvals for our product candidates; the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval; the pricing and reimbursement of our product candidates, if approved; our ability to retain the continued service of our key employees and to identify, hire and retain additional qualified employees; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy and the scope of protection we are able to establish and maintain for the intellectual property rights covering our product candidates and technology; our ability to identify and develop additional product candidates and technologies with significant commercial potential; our plans and ability to enter into collaborations or strategic partnerships for the development and commercialization of our product candidates; the potential benefits of any future collaboration or strategic partnerships; our existing cash, cash equivalents and marketable securities; our financial performance, including our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; developments relating to our competitors and our industry; the impact of government laws and regulations; and our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; the impact of being a Foreign Private Issuer and the impact of the pandemic caused by the novel coronavirus known as COVID-19 as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in our filings made from time to time with the Securities and Exchange Commission. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Except as required by law, we are under no duty to update any of these forward-looking statements after the date of this presentation to conform our prior statements to actual results or revised expectations.

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties or us. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. All of the market data used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. The industry in which we operate is subject to a high degree of uncertainty, change and risk due to a variety of factors, which could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.

This presentation is solely for the information of the recipients and may not be used, reproduced or distributed without the consent of the Company, except that you may, without the Company's consent, share an original copy of this presentation with other members of your organization who you deem have a valid business reason for reviewing it. By accepting this presentation, you acknowledge that you are solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company's business.

EVAXION highlights

US-listed AI-immunotherapy company

Cutting edge AI-platforms for target discovery

Clinical pipeline of personalized cancer immunotherapies

Why use AI for cancer?

New targets must be identified for each patient for optimal activation of the immune system



And why is that?

Unique tumor in every patient

Unique Immune system in every patient

PIONEER - Truly Personalized Immunotherapy



Sampling **Sequencing** **Targeting** **Manufacturing** **Treatment** **Effect**

EVX-01: Strong interim data in clinical phase I/II

Study in brief:

- Metastatic melanoma
- Interim data from 9 patients
- Tumor-specific immune response in all patients
- Tumor reduction in 6 out of 9 patients (cf Keytruda 33%)



EVX-01: A patient case

PATIENT

64y

DIAGNOSIS

Stage IV metastatic melanoma

STATUS

Stable disease after 10 months with anti-PD1

EFFECT

Strong immune activation by EVX-01

RESULT

Complete response

Scan at enrollment.



Scan 1 year after starting EVX-01



EVX-01: Global clinical phase IIb trial started

Locations: up to **25 sites** in Australia, Europe, USA

Trial Population: **80 patients** with metastatic melanoma

Status: Enrollment started – **first patient enrolled** in AUS in September

Interim **read-out 2023**

Business model



Immunotherapy Pipeline

	AI platform	Candidate	Stage of development: Preclinical	Phase 1	Phase 2
Oncology	PIONEER Personalized cancer immunotherapies	EVX-01 (Liposomal/peptide) Metastatic melanoma	CTCSA with Merck & Co.		2a / 2b MERCK
		EVX-02 (DNA) Adjuvant melanoma			
		EVX-03 (Targeted DNA) NSCLC			
Infectious diseases	EDEN Vaccines against bacterial diseases	EVX-B1 (Proteins) *S. aureus,* SSTI			
		EVX-B2 *N. gonorrhoeae*	NIH		
	RAVEN Vaccines against viral diseases	EVX-V1 Multiple viruses			

EVX-03 Next-generation DNA-based cancer therapy



Neo-antigen unit



APC targeting unit Dimerization domain Neo-antigen unit

Growing market

Cancer immunotherapy market est. to USD 277 billion in 2030*

*Precedence Research

NSCLC market est. to USD 33 billion by 2029**

**GlobalData

Melanoma market Est. to USD 7.4 billion by 2029**

**GlobalData

Increased deal-making

Nykode-Roche out-licensing deal (2020). Upfront + early MS of USD 200M and royalty ≈ 10%

Gritstone-BMS clinical trial collaboration (2018). No financials disclosed

Moderna-Merck partnership. Upfront USD 200M (2016) + option exercise USD 250M (Oct 2022)

BioNTech-Neon Therapeutics M&A. USD 67M (2020)

Milestones

H2 2022 First viral candidate EVX-V1

H1 2023 Readout EVX-02 Phase 1/2a

H2 2023 Interim readout EVX-01 Phase 2b

Third quarter:

- Cash USD 17.9 million
- Runway · mid-2023

Financial vehicles in place for extending runway further

5 things to remember

- Leading AI platforms
- Strong clinical efficacy data
- Huge & fast-growing market
- Hot field for deal-making
- Next major clinical milestone: Interim Ph2b in H2 2023

Linkedin: Evaxion Biotech

Investor@evaxion-biotech.com

evaxion-biotech.com



Thank you

AI-Powered Immunotherapies

EVAXION